OBJECTIVE To identify prenatal and perinatal risk factors for clinically severe (stage 3 or 4) retinopathy of prematurity (ROP). METHODS Data were collected prospectively as part of the ongoing Australian and New Zealand Neonatal Network audit of high-risk infants (birth weight of <1500 g or gestational age [GA] of <32 weeks) admitted to a level III neonatal unit in Australia or New Zealand. ...

This statement revises a previous statement on screening of preterm infants for retinopathy of prematurity (ROP) that was published in 2006. ROP is a pathologic process that occurs only in immature retinal tissue and can progress to a tractional retinal detachment, which can result in functional or complete blindness. Use of peripheral retinal ablative therapy by using laser photocoagulation fo...

This statement revises a previous statement on screening of preterm infants for retinopathy of prematurity (ROP) that was published in 2001. ROP is a pathologic process that occurs only in immature retinal tissue and can progress to a tractional retinal detachment, which can result in functional or complete blindness. Recent development of peripheral retinal ablative therapy using laser photoco...

PURPOSE To compare retinopathy of prematurity (ROP) screening experiences using binocular indirect ophthalmoscopy (BIO) and wide-field digital retinal imaging (WFDRI) at centers in Auckland, New Zealand, with those of other centers in Australasia. METHODS A web-based survey regarding methods of screening for ROP was distributed to ophthalmologists in Australia and New Zealand. RESULTS Thirt...

BACKGROUND Retinopathy of prematurity (ROP) is an eye disease caused by an alteration in retinal vasculogenesis that may lead to partial or complete vision loss with a harmful impact in terms of neurodevelopment. The purpose of the present study was to determine the neurodevelopment in patients with type i retinopathy of prematurity treated with intravitreal bevacizumab. MATERIAL AND METHODS ...

Purpose To compare corneal aberrations in former preterm infants to that of full-term infants. Methods A prospective cross-sectional study was carried out measuring the corneal shape with Scheimpflug imaging in former preterm infants of gestational age (GA) ≤32 weeks and full-term infants with GA ≥37 weeks now being aged between 4 to 10 years. The main outcome measures were corneal aberration...

PURPOSE OF REVIEW To review the most recent literature regarding the clinical experience of antivascular endothelial growth factor (anti-VEGF) therapies in the treatment of retinopathy of prematurity (ROP). RECENT FINDINGS Anti-VEGF agents in stage 3+ and aggressive posterior ROP have been shown to induce rapid ROP regression. However, significant reoccurrence rates can require repeat injecti...

This statement revises a previous statement on screening of preterm infants for retinopathy of prematurity (ROP) that was published in 2006. ROP is a pathologic process that occurs only in immature retinal tissue and can progress to a tractional retinal detachment, which can result in functional or complete blindness. Use of peripheral retinal ablative therapy by using laser photocoagulation fo...

Introduction Retinopathy of prematurity (ROP) was originally designated as retrolental fibroplasias by Terry in 1952 who related it with premature birth. Term ROP was coined by Heath in 1951. It is a disorder of development of retinal blood vessels in premature babies. Normal retinal vascularization happens centrifugally from optic disc to ora. Vascularization up to nasal ora is completed by 8 ...